Nuedexta for the Treatment of Adults With Autism

Summary

Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8 weeks over subjects given placebo. Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by Overt Aggression Scale (OAS).

Timeline

Start

2012-01-24

Primary completion

2015-12-15

Completion

2015-12-15

Drugs

Indications